OmniComm Systems (OMCM) Stock Price, News & Analysis

Company Overview

OmniComm Systems (OTCMKTS: OMCM) is a developer of cloud-based software solutions designed to streamline the clinical trial process for pharmaceutical, biotechnology and medical device companies. The company’s flagship platforms support electronic data capture (EDC), clinical trial management (CTMS), electronic patient-reported outcomes (ePRO/eCOA) and risk-based monitoring in a unified environment. These tools enable researchers and trial sponsors to collect, manage and analyze clinical data in real time, improving data quality and operational efficiency.

OmniComm’s product suite includes its TrialMaster EDC system, a widely used application for capturing clinical trial data, and the TrialOne CTMS module, which provides comprehensive study planning, site management, monitoring and reporting capabilities. The company also offers integrated solutions for mobile data collection, safety reporting and data integration, allowing clients to tailor workflows to the unique requirements of each study. OmniComm’s software is delivered through a secure, validated cloud infrastructure that supports global regulatory compliance.

Founded in the early 1990s and headquartered in South Florida, OmniComm Systems has expanded its presence with regional offices and partners across North America, Europe and Asia-Pacific. Over the years, the company has served a diverse customer base ranging from small biotech firms to large multinational pharmaceutical organizations. Its solutions have been deployed in studies spanning therapeutic areas such as oncology, cardiology, neurology and rare diseases.

Under the guidance of its experienced management team, OmniComm continues to invest in product innovation and customer support. The company’s leadership brings together expertise in clinical research, software development and regulatory affairs, ensuring that its platforms evolve in step with changing industry standards and emerging trial designs. OmniComm Systems remains committed to delivering scalable, flexible technology that meets the needs of a rapidly evolving clinical research landscape.

Key Stats

• Today's Range: $0.41 to $0.41
• 50-Day Range: $0.41 to $0.41
• 52-Week Range: $0.01 to $0.44
• Volume: N/A
• Average Volume: 140,659 shs
• Market Capitalization: $66.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OMCM Stock Analysis - Frequently Asked Questions

How have OMCM shares performed this year?

OmniComm Systems' stock was trading at $0.41 at the beginning of the year. Since then, OMCM shares have increased by 0.0% and is now trading at $0.41.

How were OmniComm Systems' earnings last quarter?

OmniComm Systems, Inc. (OTCMKTS:OMCM) issued its earnings results on Tuesday, April, 3rd. The company reported $0.01 EPS for the quarter. The business earned $6.80 million during the quarter. OmniComm Systems had a negative trailing twelve-month return on equity of 13.18% and a negative net margin of 2.67%.

How do I buy shares of OmniComm Systems?

Shares of OMCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OmniComm Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OmniComm Systems investors own include Broadridge Financial Solutions (BR), Cenveo (CVO), ENGlobal (ENG), InterCloud Systems (ICLD), IntelGenx Technologies (IGXT), Nuance Communications (NUAN) and On Track Innovations (OTIV).

Company Calendar

• Last Earnings: 4/03/2018
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Business Services
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:OMCM
• CIK: 1034592
• Web: www.omnicomm.com
• Phone: 954-473-1254
• Fax: N/A
• Employees: 175
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $3.69 million
• Net Margins: -2.67%
• Pretax Margin: N/A
• Return on Equity: -13.18%
• Return on Assets: -6.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.51
• Quick Ratio: 0.51

Sales & Book Value

• Annual Sales: $27.10 million
• Price / Sales: 2.44
• Cash Flow: $0.03 per share
• Price / Cash Flow: 14.62
• Book Value: ($0.07) per share
• Price / Book: -5.86

Miscellaneous

• Outstanding Shares: 161,073,000
• Free Float: N/A
• Market Cap: $66.04 million
• Optionable: Not Optionable
• Beta: 0.67